Pembrolizumab: tested with established drugs

245 studies: they are given beside it. Page 3 of 3. Open to participants first (35), then studies with results posted, then the rest; newest registration first within each.

• LITT and Pembrolizumab in Recurrent Brain MetastasisTerminatedNCT04187872Phase 1Report a problem
• Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder CancerActive, not recruitingNCT04164082Phase 2Report a problem
• Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung CancerWithdrawnNCT04061590Phase 2Report a problem
• Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell LymphomaActive, not recruitingNCT03995147Phase 2Report a problem
• A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)CompletedNCT03988036Phase 2Report a problem
• Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or RefractorySuspendedNCT03969446Phase 1Report a problem
• Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial CancerActive, not recruitingNCT03932409Phase 1Report a problem
• Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)CompletedNCT03924856Phase 3Report a problem
• First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension StudyWithdrawnNCT03881111Phase 3Report a problem
• Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast CancerWithdrawnNCT03841747Phase 2Report a problem
• MRD-guided Treatment in NPM1mut AML PatientsTerminatedNCT03769532Phase 2Report a problem
• Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA)CompletedNCT03732391Phase 2Report a problem
• Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)Active, not recruitingNCT03725059Phase 3Report a problem
• Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)Active, not recruitingNCT03711032Phase 3Report a problem
• Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 InhibitorsStatus unknownNCT03656094Phase 2Report a problem
• Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast CancerWithdrawnNCT03644589Phase 2Report a problem
• Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma PatientsCompletedNCT03630159Phase 1Report a problem
• Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary SyndromeWithdrawnNCT03617224Phase 1Report a problem
• Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian CancerStatus unknownNCT03539328Phase 2Report a problem
• Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseActive, not recruitingNCT03516279Phase 2Report a problem
• Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast CancerActive, not recruitingNCT03515798Phase 2Report a problem
• Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]Active, not recruitingNCT03504163Phase 2Report a problem
• Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell CarcinomaCompletedNCT03480672Phase 2Report a problem
• Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for SurgeryStatus unknownNCT03446911Phase 1/2Report a problem
• Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube CancerStatus unknownNCT03410784Phase 2Report a problem
• Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)Active, not recruitingNCT03407144Phase 2Report a problem
• Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBCCompletedNCT03289819Phase 2Report a problem
• Pembrolizumab in Biliary Tract CancerCompletedNCT03260712Phase 2Report a problem
• Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric CancerActive, not recruitingNCT03257163Phase 2Report a problem
• Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic CyclophosphamideCompletedNCT03139851Phase 2Report a problem
• Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian CancerCompletedNCT03126812Phase 1/2Report a problem
• Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer PatientsStatus unknownNCT03053856Phase 2Report a problem
• Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast CancerTerminatedNCT02990845Phase 1/2Report a problem
• Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLCTerminatedNCT02987998Phase 1Report a problem
• Anti PD-1 Neo-adjuvant Treatment for NSCLCCompletedNCT02938624Phase 1Report a problem
• Pembrolizumab, Trastuzumab, HER2 Positive Gastric CancerStatus unknownNCT02901301Phase 1/2Report a problem
• Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell CarcinomaCompletedNCT02775812Phase 1Report a problem
• A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast CancerActive, not recruitingNCT02755272Phase 2Report a problem
• A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural MesotheliomaTerminatedNCT02707666Phase 1Report a problem
• Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular LymphomaCompletedNCT02677155Phase 2Report a problem
• Trial of Chemoradiation and Pembrolizumab in Patients With Rectal CancerWithdrawnNCT02586610Phase 2Report a problem
• Pembrolizumab in Untreated Extensive SCLCCompletedNCT02580994Phase 2Report a problem
• Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed GlioblastomaTerminatedNCT02530502Phase 1Report a problem
• Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial CancerCompletedNCT02437370Phase 1Report a problem
• Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)TerminatedNCT02331251Phase 1/2Report a problem

← Pembrolizumab